EFFICACY AND SAFETY OF XILOGLUCAN IN ACUTE GASTROENTERITIS IN CHILDREN

Phase

N/A

Condition

Gastroenteritis

Colic

Lactose Intolerance

Treatment

N/A

Clinical Study ID

NCT03357237

PEDXIL 01

Ages 3-5
All Genders

Study Summary

Acute gastroenteritis (GEA) is an inflammation of the intestinal mucosa that clinically translates into an acute episode of diarrhea and vomiting and is generally associated with an intestinal infectious disease. It is one of the most common diseases in children and an important cause of morbidity and mortality worldwide. The important loss of liquids can lead to dehydration, acidosis and hydroelectrolitic alteration. Infants are more vulnerable to gastrointestinal infection and its consequences, dehydration and malnutrition.

There is no specific treatment, so it is exclusively symptomatic

A new type of products considered as mucoprotectors has been developed, such as gelatin tannate or xyloglucan, still with little data to establish recommendations on its use in the GEA. They would be able to reproduce in the intestine a muco-adhesive film or sheet protective It must be considered in this sense that mucus is the first barrier that protects the gastrointestinal tract against microorganisms or antigens and that bacterial invasion is related to the opening of narrow junctions.

Xyloglucan was approved in Europe as a medical device IIa to restore the physiological functions of the intestinal wall in the form of capsules for adults and envelopes for children.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Clinical of acute gastroenteritis: change in the consistency of stools to "loose" orliquid according to Bristol scale (6 or 7) or Amsterdam (infants) (A) and / orincrease in the number of stools (greater or equal to 3 / day) with a duration of lessthan 72 h
Age over 3 months and under 5 years
Written informed consent according to ICH / GCP and local legislation, obtained beforeany study procedure of parents or guardians

Exclusion

Exclusion Criteria:

Treatment with antibiotics, xyloglucan, gelatin tannate, racecadotril, smectite,probiotics or zinc (including oral rehydration solution containing zinc and / orprobiotics) in the previous week
Exclusive breastfeeding
Chronic gastrointestinal disease (celiac disease, cystic fibrosis, inflammatory boweldisease, food allergy)
Immunodeficiencies
Malnutrition (weight / height / length less than P3 according to WHO standards)
Severe dehydration
Impossibility of follow-up
Known hypersensitivity to gelatin or xyloglucan
Absence of informed consent
Caregivers / parents who can not understand or comply with all the instructions andrequirements of the study.
If in the opinion of the researcher there are findings in the physical examination,abnormalities in the results of the clinical analyzes or other medical, social orpsychosocial factors that could negatively influence

Study Design

December 01, 2017

July 30, 2018

Study Description

A randomized, blinded study with a control group is proposed in this project to establish solidly the efficacy of xyloglucan in the treatment of acute gastroenteritis in children.

The main variable of evaluation will be the duration of diarrhea, defined as the time it takes to normalize the consistency of stools (according to the Bristol or Amsterdam scale) or their number.

Clinical trial in phase IV with medical product type IIa and CE marking, used in the same conditions in which it is marketed.

Connect with a study center

Hospital Puerta de Hierro
Majadahonda, Madrid 28222
Spain
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.